MedTrace Logo

Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care

NCT03460483 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1001

Last updated 2025-10-03

No results posted yet for this study

Summary

This clinical trial studies universal screening for deoxyribonucleic acid (DNA) mismatch repair deficiency in patients with endometrial cancer, mutations in the genes responsible for Lynch syndrome (inherited forms of endometrial cancers) and other DNA changes that could help guide treatment strategies. Universal tumor DNA sequencing may help doctors better understand how to personalize care, increase length of life, and increase quality of life in patients with endometrial cancer and their relatives.

Conditions

  • Relatives
  • Endometrial Adenocarcinoma
  • Endometrial Carcinoma
  • Lynch Syndrome

Interventions

OTHER

Genetic Counseling

Undergo genetic counseling

OTHER

Genetic Testing

Undergo genetic testing

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Mutation Carrier Screening

Undergo tumor screening via next-generation sequencing

Sponsors & Collaborators

  • Ohio State University Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Paul Goodfellow · Ohio State University Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-30
Primary Completion
2025-06-15
Completion
2025-06-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03460483 on ClinicalTrials.gov